LSD and the heartbeat of a city
Another victim of Nixon’s ill-guided War on Drugs…
One dose of the hallucinogenic drug LSD could help alcoholics give up drinking, according to an analysis of studies performed in the 1960s. A study, presented in the Journal of Psychopharmacology, looked at data from six trials and more than 500 patients. It said there was a “significant beneficial effect” on alcohol abuse, which lasted several months after the drug was taken. Researchers at the Norwegian University of Science and Technology analysed earlier studies on the drug between 1966 and 1970.
Patients were all taking part in alcohol treatment programmes, but some were given a single dose of LSD of between 210 and 800 micrograms. For the group of patients taking LSD, 59% showed reduced levels of alcohol misuse compared with 38% in the other group.
This effect was maintained six months after taking the hallucinogen, but it disappeared after a year. Those taking LSD also reported higher levels of abstinence.
The report’s authors, Teri Krebs and Pal-Orjan Johansen, said: “A single dose of LSD has a significant beneficial effect on alcohol misuse.”
They suggested that more regular doses might lead to a sustained benefit.
“Given the evidence for a beneficial effect of LSD on alcoholism, it is puzzling why this treatment approach has been largely overlooked,” they added.
(click here to continue reading BBC News – LSD ‘helps alcoholics to give up drinking’.)
Puzzling, until you recall that the United States government is adamantly opposed to scientists being able to even research drugs like psilocybin, LSD and marijuana, no matter how many promising studies occur.
Tellingly, the US media has not, to my knowledge, published this story.
Update, just took a while. So far, NPR, San Francisco Chronicle, Mother Jones, and a few other not-quite mainstream players have seen fit to run a story.
The study is available here, as PDF, if you are interested in the details…
Alcohol is said to cause more overall harm than any other drug (Nutt et al., 2010). Alcohol contributes to about 4% of total mortality and about 5% of disability adjusted life-years to the global burden of disease (Rehm et al., 2009). Despite the often extreme individual and social consequences of alcohol misuse, many users find it challenging to stop drinking. Alcoholism, also called alcohol dependence, continues to be difficult to treat, and many patients do not achieve recovery from existing treatments (Schuckit, 2009).
Numerous clinical investigators have claimed that treating alcoholics with individual doses of lysergic acid diethylamide (LSD), in combination with psychosocial interventions, can help to prevent a relapse of alcohol misuse, for example, by eliciting insights into behavioural patterns and generating motivation to build a meaningful sober lifestyle (Dyck, 2008). LSD is well- known for inducing spectacular and profound effects on the mind (Henderson and Glass, 1994; Passie et al., 2008). It has previously been used in standard treatment programs for alcoholism at many clinics, but, unfortunately, assessments of the clinical value of LSD have not been based on formal systematic review and meta- analysis (Mangini, 1998). Hence, we have performed a quantita- tive evaluation of the effectiveness of LSD for alcoholism, based on data from randomized controlled clinical trials.
Methods Search strategy and selection criteria
We searched the PubMed and PsycINFO databases (1943–2010), without language restrictions, using the following terms: LSD, lysergic, lysergide, psychedelic*, or hallucinogen*; and alcohol*, addict*, or dependence. We independently inspected the searchresults by reading the titles and abstracts. We retrieved each potentially relevant publication located in the search and assessed it for inclusion, subsequently examining the reference lists of eligible studies and relevant review articles. We supplemented our search for trials by contacting experts. If publications lacked important information, we attempted to contact study investigators and institutions.
We specified inclusion and exclusion criteria and defined primary and secondary outcomes in the meta-analysis study protocol. We included randomized controlled trials of LSD for alcoholism, in which control condition involved any type of treatment, including doses of up to 50 mcg LSD as an active control. If a trial included multiple randomized treatment arms, all participants in the eligible LSD arms and all participants in the eligible control arms were pooled for analysis. We excluded participants with schizophrenia or psychosis from analysis, as psychosis is recognized as a contraindication for treatment with LSD (Johnson et al., 2008; Passie et al., 2008).